KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (2016 - 2025)

Vertex Pharmaceuticals has reported Shares Outstanding over the past 17 years, most recently at $254.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $254.0 million for Q4 2025, down 1.15% from a year ago — trailing twelve months through Dec 2025 was $254.0 million (down 1.15% YoY), and the annual figure for FY2025 was $254.0 million, down 1.15%.
  • Shares Outstanding for Q4 2025 was $254.0 million at Vertex Pharmaceuticals, roughly flat from $254.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for VRTX hit a ceiling of $259.1 million in Q2 2021 and a floor of $254.0 million in Q3 2025.
  • Median Shares Outstanding over the past 5 years was $257.0 million (2022), compared with a mean of $256.8 million.
  • Biggest five-year swings in Shares Outstanding: dropped 2.08% in 2021 and later grew 0.98% in 2022.
  • Vertex Pharmaceuticals' Shares Outstanding stood at $254.5 million in 2021, then grew by 0.98% to $257.0 million in 2022, then grew by 0.27% to $257.7 million in 2023, then dropped by 0.29% to $256.9 million in 2024, then dropped by 1.15% to $254.0 million in 2025.
  • The last three reported values for Shares Outstanding were $254.0 million (Q4 2025), $254.0 million (Q3 2025), and $256.3 million (Q2 2025) per Business Quant data.